Search

Your search keyword '"Lorusso, Domenica"' showing total 50 results

Search Constraints

Start Over You searched for: Author "Lorusso, Domenica" Remove constraint Author: "Lorusso, Domenica" Publisher bmj publishing group Remove constraint Publisher: bmj publishing group
50 results on '"Lorusso, Domenica"'

Search Results

3. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.

6. Endometrial carcinosarcoma

7. Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors

8. Gestational choriocarcinoma.

10. Management of stage III and IVa uterine cancer

13. Interviews conducted at the European Society of Gynaecological Oncology 2022 Congress: a ENYGO- IJGC Fellows initiative.

15. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

16. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study

17. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

18. A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group.

19. Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).

20. Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial.

21. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.

22. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.

23. Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.

24. Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer --a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).

25. Expectations and preferences of patients with primary and relapsed ovarian cancer to maintenance therapy: A NOGGO/ENGOT-ov22 and GCIG survey (Expression IV).

26. Antitumor activity of the poly(ADPribose) polymerase inhibitor rucaparib as monotherapy in patients with platinumsensitive, relapsed, BRCA- mutated, highgrade ovarian cancer, and an update on safety.

27. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.

28. Capecitabine in patients with platinum-pretreated advanced or recurrent cervical carcinoma: a retrospective study.

29. Pegylated liposomal doxorubicin re-challenge in patients with ovarian cancer relapse: a multicenter retrospective study.

30. Surgical Efforts Might Mitigate Difference in Response to Neoadjuvant Chemotherapy in Stage IIIC–IV Unresectable Ovarian Cancer: A Case-Control Multi-institutional Study.

31. Factors Predictive of 90-Day Morbidity, Readmission, and Costs in Patients Undergoing Pelvic Exenteration.

32. Invasive Paget Disease of the Vulva.

33. The Impact of Number of Cycles of Neoadjuvant Chemotherapy on Survival of Patients Undergoing Interval Debulking Surgery for Stage IIIC-IV Unresectable Ovarian Cancer Results From a Multi-Institutional Study.

34. Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future.

35. Impact of Blood Transfusions on Survival of Locally Advanced Cervical Cancer Patients Undergoing Neoadjuvant Chemotherapy Plus Radical Surgery.

36. Surgical Techniques for Diaphragmatic Resection During Cytoreduction in Advanced or Recurrent Ovarian Carcinoma.

38. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix.

39. Gynecologic Cancer Intergroup (GCIG) Consensus Review for Ovarian Germ Cell Tumors.

40. Trophoblastic Disease Review for Diagnosis and Management.

41. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Carcinoid Tumors of the Ovary.

42. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary.

43. Carboplatin-Paclitaxel Versus Cisplatin-Ifosfamide in the Treatment of Uterine Carcinosarcoma.

44. Phase II Trial on Cisplatin-Adriamycin-Paclitaxel Combination as Neoadjuvant Chemotherapy for Locally Advanced Cervical Adenocarcinoma.

45. Phase 2 Trial of Nonpegylated Doxorubicin (Myocet) as Second-Line Treatment in Advanced or Recurrent Endometrial Cancer.

46. Outcome and Risk Factors for Recurrence in Malignant Ovarian Germ Cell Tumors.

47. Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer.

48. Use of the Poly (ADP-Ribose) Polymerase Inhibitor Rucaparib in Women with Recurrent Ovarian Carcinoma with Endometrioid and Other Nonserous Histopathologic Subtypes.

49. Recurrent High-Grade Vaginal Intraepithelial Neoplasia.

50. Surgery allows long-term control in advanced stage low-grade serous ovarian cancer.

Catalog

Books, media, physical & digital resources